CN113648431A - siRNA nucleic acid liposome targeting BIRC6 gene and preparation method and application thereof - Google Patents

siRNA nucleic acid liposome targeting BIRC6 gene and preparation method and application thereof Download PDF

Info

Publication number
CN113648431A
CN113648431A CN202110898374.XA CN202110898374A CN113648431A CN 113648431 A CN113648431 A CN 113648431A CN 202110898374 A CN202110898374 A CN 202110898374A CN 113648431 A CN113648431 A CN 113648431A
Authority
CN
China
Prior art keywords
birc6
sirna
liposome
gene
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110898374.XA
Other languages
Chinese (zh)
Inventor
谭亚南
关新元
李咏梅
李珊珊
罗敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Hospital University of Hong Kong
Original Assignee
Shenzhen Hospital University of Hong Kong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Hospital University of Hong Kong filed Critical Shenzhen Hospital University of Hong Kong
Priority to CN202110898374.XA priority Critical patent/CN113648431A/en
Publication of CN113648431A publication Critical patent/CN113648431A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a siRNA nucleic acid liposome targeting a BIRC6 gene and a preparation method and application thereof, wherein the siRNA nucleic acid liposome targeting the BIRC6 gene comprises a liposome component and a BIRC6 inhibitor; the liposome component comprises DOTAP, Chol, DPPC and DSPE-PEG 2000; the BIRC6 inhibitor is siRNA targeting BIRC6, and the siRNA sequence of the BIRC6 is GUUUCAAGCAGGAUGAUGdTdT. The siRNA nucleic acid liposome provided by the invention has positive electricity on the surface, is not easily degraded by nuclease, can enable the loaded siRNA to enter a cell targeting silencing BIRC6 gene, and can effectively inhibit the proliferation and tumor formation of triple negative breast cancer cells, thereby achieving the purpose of treating triple negative breast cancer. The siRNA nucleic acid liposome has good cell uptake and lysosome escape capacity, has the BIRC6 targeting property, is beneficial to the targeted transportation of gene drugs in vivo, and realizes the long circulation in gene drug objects and the targeted silencing effect on BIRC6 high-expression tumors.

Description

siRNA nucleic acid liposome targeting BIRC6 gene and preparation method and application thereof
Technical Field
The invention relates to the technical field of drug delivery, in particular to siRNA nucleic acid liposome targeting BIRC6 gene and a preparation method and application thereof.
Background
Triple-negative breast cancer (TNBC) is a type of breast cancer in which ER and PgR expression are deleted and HER2 is overexpressed or gene amplification is deleted, and accounts for 12% -17% of all breast cancers. TNBC is biologically more aggressive, with a higher recurrence rate in patients and a worse 5 year prognosis compared to other subtypes. Although the PARP inhibitor, PD-L1 antibody atezolizumab, is currently approved for TNBC patients with BRCA mutations, positive for PD-L1 expression, respectively, targeted therapy against TNBC is still in the early stages and chemotherapy remains the standard treatment. TNBC patients, despite having a certain response rate to chemotherapy, still have 60% -70% of patients who are not susceptible to chemotherapy. Therefore, there is an urgent need to identify more molecular targets that can be used for TNBC therapy and to develop corresponding targeted therapeutic approaches.
BIRC6 is a very large (near 530kDa) and less studied member of the Inhibitor of Apoptosis Protein (IAP) family. Our previous studies found that BIRC6 is highly expressed in triple negative breast cancer, and that overexpression can promote proliferation of triple negative breast cancer cells, and is associated with short prognosis survival time of triple negative breast cancer patients, revealing that silencing BIRC6 expression is expected to be useful in triple negative breast cancer treatment.
At present, there are no inhibitors that silence BIRC6 expression clinically. Gene therapy using siRNA can down-regulate the expression of abnormal genes in cancer cells and show greater potential in cancer therapy. However, unmodified siRNA is easily degraded by nuclease, and has poor cellular uptake efficiency, and clinical application is limited. At present, siRNA silencing BIRC6 gene has not been studied in the treatment drugs such as triple negative breast cancer.
Accordingly, the prior art is yet to be improved and developed.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a siRNA nucleic acid liposome targeting BIRC6 gene and a preparation method and application thereof.
The technical scheme of the invention is as follows:
an siRNA nucleic acid liposome targeting BIRC6 gene, which comprises liposome components and a BIRC6 inhibitor; the liposome component comprises DOTAP, Chol, DPPC and DSPE-PEG 2000; the BIRC6 inhibitor is siRNA targeting BIRC6, and the siRNA sequence of the BRIC6 is GUUUCAAGCAGGAUGAUGdTdT.
The siRNA nucleic acid liposome targeting the BIRC6 gene comprises 70 parts of DPPC, 0-20 parts of DOTAP, 5 parts of Chol and 5 parts of DSPE-PEG2000 in parts by weight.
The siRNA nucleic acid liposome targeting the BIRC6 gene is characterized in that the mass ratio of the liposome component to the BIRC6 inhibitor is 10-100: 1.
The siRNA nucleic acid liposome targeting the BIRC6 gene is characterized in that the mass ratio of the liposome component to the BIRC6 inhibitor is 60: 1.
A method for preparing siRNA nucleic acid liposome targeting BIRC6 gene comprises the following steps:
dissolving DPPC, DOTAP, Chol and DSPE-PEG2000 in ethanol, and heating in water bath at 60 deg.C to obtain ethanol phase solution;
rapidly dispersing the ethanol phase solution into an F68 aqueous solution, stirring at the rotating speed of 400rpm for 8min, and cooling the prepared solution at room temperature to obtain a PEG modified cationic liposome solution;
preparing siRNA targeting BIRC6 into an siRNA solution with the concentration of 2 mu M by DEPC water, mixing the siRNA solution with the PEG modified cationic liposome solution according to a set mass ratio, whirling for 30s, and standing for 30min at room temperature to obtain the siRNA nucleic acid liposome targeting BIRC6 gene.
An application of siRNA nucleic acid liposome targeting BIRC6 gene in preparing a medicament for treating or preventing diseases caused by abnormal expression of BIRC6 gene.
The use of (a), wherein the disease is triple negative breast cancer.
A liposome preparation, wherein the siRNA nucleic acid liposome targeting BIRC6 gene and a pharmaceutically acceptable carrier are contained.
Has the advantages that: the invention provides a siRNA nucleic acid liposome targeting BIRC6 gene, which is formed by combining a cationic liposome component and a BIRC6 inhibitor and then forming the siRNA nucleic acid liposome in an electrostatic adsorption mode. The cationic liposome has positive charges, and can be tightly combined with siRNA with negative charges through electrostatic action to form a compound of the liposome and nucleic acid, so that escape of an endo-lysosome is promoted, the nucleic acid is protected from degradation by nuclease, and guarantee is provided for further drug effect exertion of nucleic acid drugs; on the other hand, the PEG phospholipid is introduced, so that the phagocytosis of the nanoparticles by macrophages of a reticuloendothelial system can be reduced, the in vivo long circulation is realized, the retention and accumulation time of a nucleic acid delivery system in tumor tissues is prolonged, the toxic and side effects are reduced, and the high-efficiency and low-toxicity treatment target is realized. The siRNA nucleic acid liposome has positive electricity on the surface, is not easily degraded by nuclease, can enable the loaded siRNA to enter a cell targeting silent BIRC6 gene, and can effectively inhibit the proliferation and tumor formation of triple negative breast cancer cells, thereby achieving the purpose of treating triple negative breast cancer; the siRNA nucleic acid liposome targeting the BIRC6 gene is beneficial to targeted transportation of a gene medicament in vivo, can improve the treatment efficiency of triple negative breast cancer, and has important significance for the targeted treatment of BIRC6 high-expression tumors by the gene medicament.
Drawings
FIG. 1 shows the preparation process of siRNA nucleic acid liposome targeting BIRC6 gene.
FIG. 2 shows the particle size and surface potential of pCLNs containing DOTAP in different mass ratios.
FIG. 3 shows gel electrophoresis block diagram of siRNA nucleic acid liposomes.
FIG. 4 shows the particle size and potential of siRNA nucleic acid liposomes.
The results shown in fig. 5, a to C, show that siRNA nucleic acid liposomes can efficiently deliver siRNA targeting BIRC6 to triple negative breast cancer cells in vitro and in vivo, a shows that after MDA-MB-468 cells were incubated with free Cy3-siRNA or pCLNs/Cy3-siRNA for a specified time, intracellular fluorescence intensity of Cy3-siRNA was measured with a flow cytometer; b shows that after MDA-MB-468 cells are incubated with pCLNs/Cy3-siRNA for a specified time, the intracellular localization and lysosome escape of liposomes are observed by laser confocal scanning microscopy; c shows that after intravenous injection of free Cy3-siRNA or pCLNs/Cy3-siRNA into MDA-MB-468 xenograft tumor mice, their in vivo distribution was observed.
The results shown in a to G in fig. 6 show that siRNA nucleic acid liposome can significantly inhibit proliferation and tumor formation of triple negative breast cancer cells, a shows protein expression of BIRC6 in MDA-MB-468 cells treated with nucleic acid liposome (left) and relative cell proliferation rate (right); b shows the apoptosis ratio of MDA-MB-468 cells after being treated by nucleic acid liposome and EGFR inhibitor gefitinib; C-E shows representative pictures of MDA-MB-468 xenografts treated with nucleic acid liposomes and the EGFR inhibitor gefitinib (C), tumor volume (D) and tumor weight (E); f shows immunohistochemical analysis of MDA-MB-468 xenograft tumors treated with nucleic acid liposomes and an EGFR inhibitor gefitinib; g shows the mean fluorescence intensity of Ki67 and clear caspase3 staining.
Detailed Description
The invention provides a siRNA nucleic acid liposome targeting BIRC6 gene and a preparation method and application thereof, and a person skilled in the art can realize the siRNA nucleic acid liposome by appropriately improving process parameters by referring to the content. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. The experimental procedures, in which specific conditions are not specified in the examples below, are generally carried out according to conventional conditions or according to conditions recommended by the manufacturers. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.
Example 1
Preparation of PEG modified cationic liposome
The PEG-modified cationic liposome provided in this example 1 is prepared by the following steps:
according to the weight portion, 70 portions of thermosensitive lipid DPPC (dipalmitoylphosphatidylcholine), 0 portion of DOTAP ((2, 3-dioleoyl-propyl) -trimethylamine), 5 portions of Chol (cholesterol) and 5 portions of DSPE-PEG2000 (distearoylphosphatidylethanolamine-polyethylene glycol 2000) are dissolved in ethanol solution and heated in water bath at 60 ℃. 2mL of an aqueous solution of F68 (1mg/mL) was heated to 60 ℃. The ethanol phase solution was rapidly dispersed into an aqueous solution of F68 at 60 ℃ and stirred at 400rpm for 8 min. And cooling the prepared solution at room temperature to obtain the PEG modified cationic liposome (pCLNs).
Example 2
Preparation of PEG modified cationic liposome
The PEG-modified cationic liposome provided in this example 2 is prepared by the following steps:
according to the weight portion, 70 portions of thermosensitive lipid DPPC (dipalmitoylphosphatidylcholine), 5 portions of DOTAP ((2, 3-dioleoyl-propyl) -trimethylamine), 5 portions of Chol (cholesterol) and 5 portions of DSPE-PEG2000 (distearoylphosphatidylethanolamine-polyethylene glycol 2000) are dissolved in ethanol solution and heated in water bath at 60 ℃. 2mL of an aqueous solution of F68 (1mg/mL) was heated to 60 ℃. The ethanol phase solution was rapidly dispersed into an aqueous solution of F68 at 60 ℃ and stirred at 400rpm for 8 min. And cooling the prepared solution at room temperature to obtain the PEG modified cationic liposome (pCLNs).
Example 3
Preparation of PEG modified cationic liposome
The PEG-modified cationic liposome provided in this example 3 is prepared by the following steps:
according to the parts by weight, 70 parts of thermosensitive lipid DPPC (dipalmitoylphosphatidylcholine), 10 parts of DOTAP ((2, 3-dioleoyl-propyl) -trimethylamine), 5 parts of Chol (cholesterol) and 5 parts of DSPE-PEG2000 (distearoylphosphatidylethanolamine-polyethylene glycol 2000) are dissolved in an ethanol solution and heated in a water bath at 60 ℃. 2mL of an aqueous solution of F68 (1mg/mL) was heated to 60 ℃. The ethanol phase solution was rapidly dispersed into an aqueous solution of F68 at 60 ℃ and stirred at 400rpm for 8 min. And cooling the prepared solution at room temperature to obtain the PEG modified cationic liposome (pCLNs).
Example 4
Preparation of PEG modified cationic liposome
The PEG-modified cationic liposome provided in this example 4 is prepared by the following steps:
according to the parts by weight, 70 parts of thermosensitive lipid DPPC (dipalmitoylphosphatidylcholine), 20 parts of DOTAP ((2, 3-dioleoyl-propyl) -trimethylamine), 5 parts of Chol (cholesterol) and 5 parts of DSPE-PEG2000 (distearoylphosphatidylethanolamine-polyethylene glycol 2000) are dissolved in an ethanol solution and heated in a water bath at 60 ℃. 2mL of an aqueous solution of F68 (1mg/mL) was heated to 60 ℃. The ethanol phase solution was rapidly dispersed into an aqueous solution of F68 at 60 ℃ and stirred at 400rpm for 8 min. And cooling the prepared solution at room temperature to obtain the PEG modified cationic liposome (pCLNs).
The particle size and surface potential of pCLNs containing DOTAP with different mass ratios are respectively measured by a particle size and surface potential meter. As a result, as shown in FIG. 2, when the weight part of the DOTAP component was 0 part, the particle diameter of pCLNs was 65.47. + -. 1.0nm, and the surface potential was-11.4. + -. 1.89 mV. As the proportion of the DOTAP component in parts by weight was gradually increased to 20 parts, the particle diameter of pCLNs was 100.2. + -. 11.2nm and the surface potential was 40.6. + -. 4.41 mV. The results show that as the proportion of the DOTAP component increases, the particle size of the pCLNs increases, but still remains around 100nm, and can be preferentially aggregated to tumor tissues through an "enhanced penetration and retention" (EPR) effect during in vivo transport; the surface charge is reversed from negative charge to positive charge and is more than 30mV, which is beneficial to stabilizing the composite siRNA with negative charge and protecting the siRNA from degradation of nuclease.
Example 5
1) Preparation of PEG modified cationic liposome
The preparation method of the PEG-modified cationic liposome provided in this example 5 is the same as that in example 4 and is not set forth herein.
2) Preparation of a composite siRNA liposome:
the composite siRNA liposome provided in this example 5 was prepared by the following steps:
the siRNA of the BIRC6 gene is prepared into siRNA solution with the concentration of 2 mu M by DEPC water, and the siRNA sequence of the BIRC6 gene is preferably GUUUCAAGCAGGAUGAUGdTdT. The siRNA solution and the PEG-modified cationic liposome pCLNs solution were slowly mixed at a set mass ratio (mass of pCLNs: siRNA mass 10: 1), vortexed for 30s, and then allowed to stand at room temperature for 30min to obtain a pCLNs/siRNA complex (as shown in fig. 1).
Example 6
1) Preparation of PEG modified cationic liposome
The preparation method of the PEG-modified cationic liposome provided in this example 6 is the same as that in example 4 and is not set forth herein.
2) Preparation of a composite siRNA liposome:
the composite siRNA liposome provided in this example 6 is prepared by the following steps:
the siRNA of the BIRC6 gene is prepared into siRNA solution with the concentration of 2 mu M by DEPC water, and the siRNA sequence of the BIRC6 gene is preferably GUUUCAAGCAGGAUGAUGdTdT. The siRNA solution and the PEG-modified cationic liposome pCLNs solution were slowly mixed at a set mass ratio (mass of pCLNs: siRNA mass 20: 1), vortexed for 30s, and then allowed to stand at room temperature for 30min to obtain a pCLNs/siRNA complex (as shown in fig. 1).
Example 7
1) Preparation of PEG modified cationic liposome
The preparation method of the PEG-modified cationic liposome provided in this example 7 is the same as that in example 4 and is not set forth herein.
2) Preparation of a composite siRNA liposome:
the complex siRNA liposome provided in this example 7 was prepared by the following steps:
the siRNA of the BIRC6 gene is prepared into siRNA solution with the concentration of 2 mu M by DEPC water, and the siRNA sequence of the BIRC6 gene is preferably GUUUCAAGCAGGAUGAUGdTdT. The siRNA solution and the PEG-modified cationic liposome pCLNs solution were slowly mixed at a set mass ratio (pCLNs mass: siRNA mass: 40: 1), vortexed for 30s, and then allowed to stand at room temperature for 30min to obtain a pCLNs/siRNA complex (as shown in fig. 1).
Example 8
1) Preparation of PEG modified cationic liposome
The preparation method of the PEG-modified cationic liposome provided in this example 8 is the same as that in example 4 and is not set forth herein.
2) Preparation of a composite siRNA liposome:
the complex siRNA liposome provided in this example 8 is prepared by the following steps:
the siRNA of the BIRC6 gene is prepared into siRNA solution with the concentration of 2 mu M by DEPC water, and the siRNA sequence of the BIRC6 gene is preferably GUUUCAAGCAGGAUGAUGdTdT. The siRNA solution and the PEG-modified cationic liposome pCLNs solution were slowly mixed at a set mass ratio (pCLNs mass: siRNA mass 60: 1), vortexed for 30s, and then allowed to stand at room temperature for 30min to obtain a pCLNs/siRNA complex (as shown in fig. 1).
Example 9
1) Preparation of PEG modified cationic liposome
The preparation method of the PEG-modified cationic liposome provided in this example 9 is the same as that in example 4 and is not set forth herein.
2) Preparation of a composite siRNA liposome:
the complex siRNA liposome provided in this example 9 is prepared by the following steps:
the siRNA of the BIRC6 gene is prepared into siRNA solution with the concentration of 2 mu M by DEPC water, and the siRNA sequence of the BIRC6 gene is preferably GUUUCAAGCAGGAUGAUGdTdT. The siRNA solution and the PEG-modified cationic liposome pCLNs solution were slowly mixed at a set mass ratio (pCLNs mass: siRNA mass: 100: 1), vortexed for 30s, and then allowed to stand at room temperature for 30min to obtain a pCLNs/siRNA complex (as shown in fig. 1).
To test the optimal mass ratio of liposome components to siRNA in the pCLNs/siRNA complexes obtained in examples 5-9 of the present invention, we performed gel electrophoresis blocking experiments. First, a 1% agarose gel was prepared and ethidium bromide (final concentration 50. mu.g/100 mL) was added. Mixing the pCLNs/siRNA compound with 5 multiplied loading buffer solution, adding the mixture into a gel hole, and setting electrophoresis parameters: 100V, 30 min. After the electrophoresis is finished, the gel is taken out, observed in a gel imaging system and photographed. The results show that the mobility of siRNA through the gel is reduced with the increase of pCLNs mass, when the mass ratio of pCLNs to siRNA is 60:1, the siRNA band is completely blocked in the gel hole (as shown in FIG. 3), and the liposome is completely sealed with siRNA to form stable complex. The proportion is selected as the preferable compounding proportion of siRNA of the BIRC6 gene and PEG modified cationic liposome pCLNs.
3) The physical and chemical properties of the siRNA liposome are studied:
cationic liposomes pCLNs and pCLNs/siRNA complexes were prepared according to the methods of examples 4 and 9, the particle size and surface potential of the corresponding liposomes were determined using a microparticle size and surface potential meter, and the spatial structure of the liposomes was studied using transmission and scanning electron microscopy. The results show that pCLNs and pCLNs/siRNA complexes exhibit the conventional spherical morphology and good size uniformity of liposomes (as shown in FIG. 4A). When pCLNs were mixed with siRNA, the particle size of the liposomes changed from 100.2. + -. 11.2nm to 155.3. + -. 1.6nm and the zeta potential changed from 40.6. + -. 4.41mV to 18.9. + -. 1.31mV (as shown in FIG. 4B), indicating that the pCLNs/siRNA complex was successfully prepared.
4) Cell uptake and tumor targeting ability studies of siRNA liposomes:
siRNA liposomes were prepared according to the method in example 9, using Cy 3-labeled siRNA. Triple negative breast cancer cells MDA-MB-468 were inoculated into 24-well plates or 35mm glass-bottom dishes and incubated overnight, and pCLNs/Cy3-siRNA complexes were added for 1h, 4h and 12h of incubation, with a final siRNA concentration of 100 nM. To assess siRNA uptake by cells, cells were treated with trypsin and harvested and analyzed for fluorescence by flow cytometry. The results show that the proportion of fluorescent cells increases with increasing incubation time of pCLNs/Cy3-siRNA and remains high after 12h of incubation (as shown in FIG. 5A). In order to achieve efficient cytoplasmic gene silencing, escape of siRNA liposomes from lysosomes after entry into the cell is essential. To study the escape of siRNA from lysosome, 0.5mL Lysotracker Blue (labeled lysosome) reagent was added to cells before observation, incubated at 37 ℃ for 30min, the medium was discarded, PBS was washed, 4% paraformaldehyde was fixed and mounted, and the distribution of the complex in cells was observed by confocal laser microscopy and a fluorescent photograph was taken. As shown in FIG. 5B, after 4h incubation, red fluorescence (Cy3-siRNA) and blue fluorescence (LysoTracker) co-localized in MDA-MB-468 cells, indicating that Cy3-siRNA localized in lysosomes. After 12h incubation, the red fluorescence separated from the blue fluorescence, suggesting that Cy3-siRNA had escaped from the lysosome into the cytoplasm. The results show that the prepared siRNA liposome has good cell uptake and lysosome escape capacity.
Further, we evaluated whether pCLNs coated siRNA could reach the tumor site through the blood and be stable in circulation. Firstly, MDA-MB-468 cells are implanted into a mammary fat pad of a female nude mouse, and an in-situ triple negative breast cancer model is established. When the tumor volume reaches 100mm3In this case, pCLNs/Cy3-siRNA or free Cy3-siRNA was injected intravenously at a siRNA dose of 20. mu.g. At the indicated times after injection, mice were imaged using a Maestro in vivo imaging system. The results showed that the fluorescence intensity in the tumors of the group injected with pCLNs/Cy3-siRNA gradually increased until the fluorescence remained high after 36h of injection, while there was no fluorescence in the tumors of the group injected with Cy3-siRNA (as shown in FIG. 5C). These results indicate that the prepared siRNA nucleic acid liposomes can be efficiently delivered to tumor sites after injection and are stable in circulation.
5) In vitro therapeutic effect study of siRNA liposomes on triple negative breast cancer cells:
the pCLNs/siBIRC6 complex was prepared by selecting liposome fractions and siRNA targeting BIRC6 according to the method of example 9, and the expression level of BIRC6 was examined by immunoblotting after incubating the complex with MDA-MB-468 cells for 48 h. The results show that pCLNs/siBIRC6 enables efficient knock-down of BIRC6 (as shown on the left of FIG. 6A). Subsequently, MDA-MB-468 cells are inoculated in a 96-well plate, after adherence, corresponding liposome is added, and after incubation for 72h, the proliferation rate of the cells is detected through an MTT experiment. The results show that pCLNs/siBIRC6 can significantly inhibit cell growth (as shown on the right of FIG. 5A). Further, the corresponding liposome or the EGFR inhibitor gefitinib is added into MDA-MB-468 cells, and after incubation for 72h, the apoptosis ratio of the cells is detected by flow cytometry. The results show that the pCLNs/siBIRC6 complex significantly increased the level of apoptosis compared to gefitinib treatment (as shown in figure 6B). The results show that the prepared siRNA liposome can effectively inhibit the growth of triple negative breast cancer cells in vitro.
6) In vivo efficacy study of siRNA liposomes on triple negative breast cancer cells:
we evaluated the antitumor effect of pCLNs/siBIRC6 complex in an orthotopic nude mouse model seeded with MDA-MB-468 cells. Specifically, MDA-MB-468 cells are injected into a mammary fat pad of a female nude mouse with the age of 4-5 weeks, and when the tumor volume reaches-100 mm3At the time, the mice were randomly divided into 4 treatment groups. gefitinib is intragastrically administered at 100mg/kg daily; pCLNs/siBIRC6 (20. mu.g of siBIRC6 per injection) or an equivalent of pCLNs/siNC was injected intravenously, repeatedly 1 time per week for 6 weeks. Mouse tumor volume and weight were monitored. The results showed that pCLNs/siBIRC6 gene therapy was more effective in inhibiting tumor growth (as shown in figure 6C) and had a 91.58% reduction in tumor volume (as shown in figure 6D) compared to the gefitinib-treated group. Furthermore, the tumor weight of the pCLNs/siBIRC 6-treated group was also lower than that of the gefitinib-treated group (as shown in FIG. 6E). Subsequently, tumor tissues were removed for immunohistochemical staining and FIGS. 6F-G show that pCLNs/siBIRC6 treatment was more effective than gefitinib in blocking cell proliferation (Ki67) and inducing apoptosis (cleared caspase 3). These results show that the prepared siRNA nucleic acid liposome can effectively inhibit the tumor formation of triple negative breast cancer cells.
It is to be understood that the invention is not limited to the examples described above, but that modifications and variations may be effected thereto by those of ordinary skill in the art in light of the foregoing description, and that all such modifications and variations are intended to be within the scope of the invention as defined by the appended claims.

Claims (8)

1. An siRNA nucleic acid liposome targeting BIRC6 gene, which is characterized by comprising a liposome component and a BIRC6 inhibitor; the liposome component comprises DOTAP, Chol, DPPC and DSPE-PEG 2000; the BIRC6 inhibitor is siRNA targeting BIRC6, and the siRNA sequence of the BRIC6 is GUUUCAAGCAGGAUGAUGdTdT.
2. The siRNA nucleic acid liposome targeting BIRC6 gene in claim 1, wherein the liposome component comprises, by weight, 70 parts of DPPC, 0-20 parts of DOTAP, 5 parts of Chol and 5 parts of DSPE-PEG 2000.
3. The siRNA nucleic acid liposome targeting BIRC6 gene of claim 1, wherein the mass ratio of the liposome components and the BIRC6 inhibitor is 10-100: 1.
4. The siRNA nucleic acid liposome targeting BIRC6 gene of claim 1, wherein the mass ratio of the liposome components and the BIRC6 inhibitor is 60: 1.
5. A method for preparing siRNA nucleic acid liposome targeting BIRC6 gene as described in any one of claims 1-4, comprising the steps of:
dissolving DPPC, DOTAP, Chol and DSPE-PEG2000 in ethanol, and heating in water bath at 60 deg.C to obtain ethanol phase solution;
rapidly dispersing the ethanol phase solution into an F68 aqueous solution, stirring at the rotating speed of 400rpm for 8min, and cooling the prepared solution at room temperature to obtain a PEG modified cationic liposome solution;
preparing siRNA targeting BIRC6 into an siRNA solution with the concentration of 2 mu M by DEPC water, mixing the siRNA solution with the PEG modified cationic liposome solution according to a set mass ratio, whirling for 30s, and standing for 30min at room temperature to obtain the siRNA nucleic acid liposome targeting BIRC6 gene.
6. Use of the siRNA nucleic acid liposome targeting BIRC6 gene as described in any one of claims 1-5 in the preparation of a medicament for treating or preventing diseases caused by abnormal expression of BIRC6 gene.
7. Use according to claim 6, wherein the disease is triple negative breast cancer.
8. A liposome preparation comprising the siRNA nucleic acid liposome targeting BIRC6 gene of any one of claims 1-5 and a pharmaceutically acceptable carrier.
CN202110898374.XA 2021-08-05 2021-08-05 siRNA nucleic acid liposome targeting BIRC6 gene and preparation method and application thereof Pending CN113648431A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110898374.XA CN113648431A (en) 2021-08-05 2021-08-05 siRNA nucleic acid liposome targeting BIRC6 gene and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110898374.XA CN113648431A (en) 2021-08-05 2021-08-05 siRNA nucleic acid liposome targeting BIRC6 gene and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN113648431A true CN113648431A (en) 2021-11-16

Family

ID=78478505

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110898374.XA Pending CN113648431A (en) 2021-08-05 2021-08-05 siRNA nucleic acid liposome targeting BIRC6 gene and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113648431A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2897389A1 (en) * 2015-07-16 2017-01-16 The University Of British Columbia Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer
WO2018129622A1 (en) * 2017-01-13 2018-07-19 Wang Yuzhuo Dual targeting antisense oligonucleotides for use as apoptotic inhibitors for the treatment of cancer
CN111388424A (en) * 2020-03-30 2020-07-10 江苏大学 siRNA nucleic acid liposome targeting NEDD4 gene and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2897389A1 (en) * 2015-07-16 2017-01-16 The University Of British Columbia Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer
WO2018129622A1 (en) * 2017-01-13 2018-07-19 Wang Yuzhuo Dual targeting antisense oligonucleotides for use as apoptotic inhibitors for the treatment of cancer
CN111388424A (en) * 2020-03-30 2020-07-10 江苏大学 siRNA nucleic acid liposome targeting NEDD4 gene and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
蒋金伟等: "BIRC6在肝细胞癌中的表达及其对肝癌细胞凋亡的影响", 《重庆医科大学学报》 *

Similar Documents

Publication Publication Date Title
Chen et al. Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer
Lu et al. Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer
Zhang et al. Multifunctional tumor-targeted PLGA nanoparticles delivering Pt (IV)/siBIRC5 for US/MRI imaging and overcoming ovarian cancer resistance
US20200009050A1 (en) Pharmaceutical composition, preparation and uses thereof
Ying et al. Macrophage membrane-biomimetic adhesive polycaprolactone nanocamptothecin for improving cancer-targeting efficiency and impairing metastasis
Stigliano et al. Radiolabeled polymeric nanoconstructs loaded with docetaxel and curcumin for cancer combinatorial therapy and nuclear imaging
Zhu et al. Nanomaterials in tumor immunotherapy: new strategies and challenges
Ma et al. Polyethylenimine and sodium cholate-modified ethosomes complex as multidrug carriers for the treatment of melanoma through transdermal delivery
Hu et al. Albumin coated trimethyl chitosan-based targeting delivery platform for photothermal/chemo-synergistic cancer therapy
López-Méndez et al. Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective
JP2018504450A (en) Pharmaceutical composition combining at least two different nanoparticles and a pharmaceutical compound, its preparation and use
Tan et al. Nanobubbles containing sPD-1 and Ce6 mediate combination immunotherapy and suppress hepatocellular carcinoma in mice
Wang et al. Advancing the pharmaceutical potential of bioinorganic hybrid lipid‐based assemblies
Zhang et al. Targeted micelles with chemotherapeutics and gene drugs to inhibit the G1/S and G2/M mitotic cycle of prostate cancer
Fan et al. pH-responsive core-shell nanogels induce in situ antigen production for cancer treatment
Liu et al. Glutathione‐Scavenging Nanoparticle‐Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects
CA2476437A1 (en) Chemosensitizing with liposomes containing oligonucleotides
Ghosh et al. A decade's worth of impact: Dox loaded liposomes in anticancer activity
Fan et al. Lignin-assisted construction of sub-10 nm supramolecular self-assembly for photothermal immunotherapy and potentiating anti-PD-1 therapy against primary and distant breast tumors
Lajous et al. Hybrid Gd 3+/cisplatin cross-linked polymer nanoparticles enhance platinum accumulation and formation of DNA adducts in glioblastoma cell lines
Zhu et al. Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy
Xu et al. Ferroptosis boosted oral cancer photodynamic therapy by carrier-free Sorafenib-Ce6 self-assembly nanoparticles
CN113648431A (en) siRNA nucleic acid liposome targeting BIRC6 gene and preparation method and application thereof
CN112263565B (en) Sorafenib-gene co-loaded nano-drug for cancer treatment and preparation method and application thereof
Liu et al. Paclitaxel-loaded hybrid exosome for targeted chemotherapy of triple-negative breast cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211116